2022
Praxe podávání systémových kortikosteroidů kriticky nemocným pacientům s covidem-19 v České republice – dotazníkový průzkum (studie ASAP-C)
MALÁSKA, Jan, Filip KELLER, David CHLEBEK, Jan STAŠEK, Jan HUDEC et. al.Základní údaje
Originální název
Praxe podávání systémových kortikosteroidů kriticky nemocným pacientům s covidem-19 v České republice – dotazníkový průzkum (studie ASAP-C)
Název anglicky
Clinical practise of administration of systemic corticosteroids among critically ill patients with COVID-19 in the Czech Republic: survey (ASAP-C)
Autoři
MALÁSKA, Jan (203 Česká republika, domácí), Filip KELLER (203 Česká republika, domácí), David CHLEBEK (203 Česká republika, domácí), Jan STAŠEK (203 Česká republika, domácí), Jan HUDEC (203 Česká republika, domácí), Tereza PROKOPOVÁ (203 Česká republika, domácí), Milan KRATOCHVÍL (703 Slovensko, domácí), František DUŠKA (203 Česká republika), J. MÁCA (203 Česká republika), Kristián BRAT (703 Slovensko, domácí), Radka ŠTĚPÁNOVÁ (203 Česká republika, domácí), Adam SVOBODNÍK (203 Česká republika, domácí), Jozef KLUČKA (703 Slovensko, garant, domácí) a Petr ŠTOURAČ (203 Česká republika, domácí)
Vydání
Anesteziologie a intenzivní medicína, Praha, Česká lékařská společnost J. E. Purkyně, 2022, 1214-2158
Další údaje
Jazyk
čeština
Typ výsledku
Článek v odborném periodiku
Obor
30221 Critical care medicine and Emergency medicine
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 0.100
Kód RIV
RIV/00216224:14110/22:00126013
Organizační jednotka
Lékařská fakulta
UT WoS
000772887900001
Klíčová slova česky
ARDS; corticosteroids; COVID-19; critical care; survey
Klíčová slova anglicky
ARDS; corticosteroids; COVID-19; critical care; survey
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 24. 2. 2023 10:35, Mgr. Tereza Miškechová
V originále
Study objective: Administration of systemic corticosteroids in patients with severe COVID-19 (Coronavirus Disease 2019) has been recommended by World Health Organization (WHO) according to the RECOVERY trial results. However, there is still ongoing debate regarding the evidence supporting the dose, timing, route of administration and type of corticosteroid. This survey aimed to describe the current clinical practice of administration of systemic corticosteroids for patients with COVID-19 within Intensive Care Units (ICU) in Czech Republic. Study design: cross-sectional survey Material and methods: Electronic survey containing 15 questions was sent to the members of Czech Society of Anaesthesiol-ogy, Resuscitation and Intensive Care, Czech Society of Intensive care and Czech Pneumological and Phthisiological Society members. The results were analysed by descriptive statistic methods. Results: The survey fulfilled 233 respondents and 231 answers were eligible for analysis. The most prevalent group was attending physician with completed training in anaesthesiology and intensive care medicine (AIM) (32 %, n = 74). The most prevalent indication for initiation of corticosteroid treatment was oxygen therapy (face mask or nasal cannula) (59,3 %, n = 137) and high-flow nasal oxygen therapy (HFNC) (21,6 %, n = 50). The most preferred corticosteroid was dexamethasone (75,8 %, n = 175) at dose of 8 mg intravenously (i. v.) (48,6 %, n = 85), or dose of 6 mg i. v. (32,0 %, n = 56) followed by methylprednis-olone (25,5 %, n= 59) at dose of 80 mg i. v. (35,6 %, n = 21), and 40 mg i. v. (13,6 %, n = 8), respectively. The preferred duration of therapy was 10 days (dexamethasone 60,6 %, n = 106, methylprednisolone 20,3 %, n = 12). Conclusion: Administration of corticosteroid was dominantly initiated in patients with severe COVID-19 receiving supplemental oxygen. The corticosteroid of first choice was intravenous dexamethasone at dose of 8 mg and 6 mg for 10 days, respectively. © 2022, Czech Medical Association J.E. Purkyne. All rights reserved.
Anglicky
Study objective: Administration of systemic corticosteroids in patients with severe COVID-19 (Coronavirus Disease 2019) has been recommended by World Health Organization (WHO) according to the RECOVERY trial results. However, there is still ongoing debate regarding the evidence supporting the dose, timing, route of administration and type of corticosteroid. This survey aimed to describe the current clinical practice of administration of systemic corticosteroids for patients with COVID-19 within Intensive Care Units (ICU) in Czech Republic. Study design: cross-sectional survey Material and methods: Electronic survey containing 15 questions was sent to the members of Czech Society of Anaesthesiol-ogy, Resuscitation and Intensive Care, Czech Society of Intensive care and Czech Pneumological and Phthisiological Society members. The results were analysed by descriptive statistic methods. Results: The survey fulfilled 233 respondents and 231 answers were eligible for analysis. The most prevalent group was attending physician with completed training in anaesthesiology and intensive care medicine (AIM) (32 %, n = 74). The most prevalent indication for initiation of corticosteroid treatment was oxygen therapy (face mask or nasal cannula) (59,3 %, n = 137) and high-flow nasal oxygen therapy (HFNC) (21,6 %, n = 50). The most preferred corticosteroid was dexamethasone (75,8 %, n = 175) at dose of 8 mg intravenously (i. v.) (48,6 %, n = 85), or dose of 6 mg i. v. (32,0 %, n = 56) followed by methylprednis-olone (25,5 %, n= 59) at dose of 80 mg i. v. (35,6 %, n = 21), and 40 mg i. v. (13,6 %, n = 8), respectively. The preferred duration of therapy was 10 days (dexamethasone 60,6 %, n = 106, methylprednisolone 20,3 %, n = 12). Conclusion: Administration of corticosteroid was dominantly initiated in patients with severe COVID-19 receiving supplemental oxygen. The corticosteroid of first choice was intravenous dexamethasone at dose of 8 mg and 6 mg for 10 days, respectively. © 2022, Czech Medical Association J.E. Purkyne. All rights reserved.
Návaznosti
| CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU (Kód CEP: EF16_013/0001826) |
| ||
| LM2018128, projekt VaV |
|